AR014062A1 - COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION - Google Patents

COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION

Info

Publication number
AR014062A1
AR014062A1 ARP980106392A ARP980106392A AR014062A1 AR 014062 A1 AR014062 A1 AR 014062A1 AR P980106392 A ARP980106392 A AR P980106392A AR P980106392 A ARP980106392 A AR P980106392A AR 014062 A1 AR014062 A1 AR 014062A1
Authority
AR
Argentina
Prior art keywords
methylphenidate
composition
topical application
patient
attention deficit
Prior art date
Application number
ARP980106392A
Other languages
English (en)
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26750154&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR014062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Pharma filed Critical Noven Pharma
Publication of AR014062A1 publication Critical patent/AR014062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un método para el tratamiento del trastorno del deficit de atencion (ADD) y deficit de atencion con hiperactividad (ADHD). Estos trastornos sontratados por la aplicacion topica de una composicion que comprende metilfenidato a unpaciente que la necesita. Esta composicion está en unsistema flexible y limitado donde está presente el metilfenidato en una cantidad suficiente para alcanzar una cinética prácticamente de orden ceropara la administracion a la piel o las mucosas de un paciente durante un período de por lo menos 10 horas. La figura que se acompana demuestrasustancialmente entregas cinéticas de orden de cero en dos de los estudios representativos, como se demuestra por los perfiles de flujo relativamentehorizontales de los niveles de metilfenidato en sangre. En una realiacion, la composicion es preparada en forma de parche y, además, comprende unadhesivo.
ARP980106392A 1997-12-15 1998-12-15 COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION AR014062A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6951097P 1997-12-15 1997-12-15
US09/163,351 US6210705B1 (en) 1997-12-15 1998-09-30 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate

Publications (1)

Publication Number Publication Date
AR014062A1 true AR014062A1 (es) 2001-01-31

Family

ID=26750154

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106392A AR014062A1 (es) 1997-12-15 1998-12-15 COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION

Country Status (28)

Country Link
US (2) US6210705B1 (es)
EP (2) EP1037615B1 (es)
JP (3) JP4316800B2 (es)
KR (1) KR100633348B1 (es)
CN (1) CN1368876A (es)
AR (1) AR014062A1 (es)
AT (1) ATE260652T1 (es)
AU (1) AU752027B2 (es)
BR (1) BR9814282A (es)
CA (1) CA2315237C (es)
CZ (2) CZ2009132A3 (es)
DE (1) DE69822199T2 (es)
DK (1) DK1037615T3 (es)
ES (2) ES2219926T3 (es)
HK (2) HK1049447A1 (es)
HU (1) HU226615B1 (es)
IL (1) IL136760A0 (es)
LV (1) LV12558B (es)
NO (1) NO329974B1 (es)
NZ (1) NZ505689A (es)
PE (1) PE20000120A1 (es)
PL (1) PL195315B1 (es)
PT (1) PT1037615E (es)
RU (1) RU2233156C2 (es)
SI (1) SI20360B (es)
TR (1) TR200001736T2 (es)
TW (2) TWI242452B (es)
WO (1) WO1999030694A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
CO5261532A1 (es) * 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
ATE252903T1 (de) * 1999-12-17 2003-11-15 Celltech Pharma Europ Ltd Arzneimittel zur behandlung konvulsivischer zustände
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6905016B2 (en) * 2000-03-14 2005-06-14 Noven Pharmaceuticals, Inc. Packaging system for transdermal drug delivery systems
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
BR0207955A (pt) * 2001-03-07 2004-02-25 Hisamitsu Pharmaceutical Co Agente de emplastro
FR2822049B1 (fr) * 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
DE20221841U1 (de) * 2001-03-16 2008-05-21 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
ES2626784T3 (es) * 2003-10-28 2017-07-26 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos
CA2595400C (en) * 2005-01-20 2017-01-17 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions
ES2372004T3 (es) * 2005-01-20 2012-01-12 Institute For Molecular Medicine, Inc. Usos de derivados de metilfenidato.
US9393218B2 (en) * 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
AU2007221117A1 (en) * 2006-02-27 2007-09-07 Noven Pharmaceuticals, Inc. Transdermal therapeutic system comprising scopolamine
EP2012745B1 (en) * 2006-05-01 2010-10-27 Colgate-Palmolive Company Oral care composition with silicone composite
US20100104621A1 (en) * 2007-02-21 2010-04-29 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
MY162831A (en) * 2007-10-15 2017-07-31 Alza Corp Once-a-day replacement transdermal administration of fentanyl
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
FR2924350B1 (fr) * 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009088726A2 (en) * 2007-12-31 2009-07-16 Acclarent, Inc. Mucosal tissue dressing and method of use
FR2926466B1 (fr) * 2008-01-23 2010-11-12 Dbv Tech Procede de fabrication de patchs par electrospray
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5155128B2 (ja) * 2008-12-11 2013-02-27 日東電工株式会社 メチルフェニデート貼付製剤
WO2010141587A1 (en) * 2009-06-05 2010-12-09 Megtec Systems, Inc. Improved infrared float bar
EP2364695A1 (en) 2010-02-10 2011-09-14 Nitto Denko Corporation Methylphenidate patch preparation
US20110200663A1 (en) * 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
ES2644942T3 (es) 2011-03-23 2017-12-01 Ironshore Pharmaceuticals & Development, Inc. Métodos y composiciones para el tratamiento del trastorno por déficit de atención
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
PL2736510T3 (pl) * 2011-07-28 2017-07-31 Kempharm, Inc. Proleki metylofenidatu, procesy ich wytwarzania i stosowania
CA2891467A1 (en) 2012-10-15 2014-04-24 Noven Pharmaceuticals, Inc. Compositions and methods for the transdermal delivery of methylphenidate
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
ES2864327T3 (es) 2012-12-28 2021-10-13 Noven Pharma Composiciones de múltiples polímeros para la administración transdérmica de fármacos
US9314470B2 (en) 2012-12-28 2016-04-19 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11337936B2 (en) 2013-03-14 2022-05-24 Noven Pharmaceuticals, Inc. Amphetamine transdermal compositions with acrylic block copolymer
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
AR095260A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones de anfetaminas transdérmicas estables y métodos de fabricación
BR112016014236A2 (pt) 2013-12-25 2017-08-08 Fujimoto Co Ltd Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
CN106511264A (zh) * 2016-11-15 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸哌甲酯口服溶液剂及其制备方法
AU2017371327B2 (en) 2016-12-11 2020-10-15 Zevra Therapeutics, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3598982A1 (en) 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
BR9306816A (pt) 1992-07-28 1998-12-08 Procter & Gamble Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado
CH691209A5 (de) 1993-09-06 2001-05-15 Scherrer Inst Paul Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten.
EP0689920B1 (de) 1994-06-29 1999-10-13 Hennecke GmbH Verfahren und Vorrichtung zum kontinuierlichen Herstellen von Schaumstoffblöcken oder Schaumstoffbahnen
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU2590697A (en) 1997-03-07 1998-09-22 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, s ystems and methods
GB9711032D0 (en) 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
EP1710504A2 (en) 1999-12-15 2006-10-11 Osaka Gas Co., Ltd. Burner Apparatus, Gas Turbine Engine and Cogeneration System

Also Published As

Publication number Publication date
KR100633348B1 (ko) 2006-10-16
DK1037615T3 (da) 2004-07-12
JP2013056944A (ja) 2013-03-28
ES2452517T3 (es) 2014-04-01
HK1049447A1 (zh) 2003-05-16
PT1037615E (pt) 2004-07-30
PL195315B1 (pl) 2007-08-31
PL341596A1 (en) 2001-04-23
CZ300535B6 (cs) 2009-06-10
JP2002510600A (ja) 2002-04-09
NO20003096L (no) 2000-08-15
KR20010033114A (ko) 2001-04-25
IL136760A0 (en) 2001-06-14
EP1037615A2 (en) 2000-09-27
TWI244396B (en) 2005-12-01
NZ505689A (en) 2003-01-31
PE20000120A1 (es) 2000-02-19
NO329974B1 (no) 2011-01-31
CA2315237C (en) 2009-12-01
DE69822199D1 (de) 2004-04-08
HUP0004539A2 (hu) 2001-06-28
SI20360A (sl) 2001-04-30
AU752027B2 (en) 2002-09-05
ES2219926T3 (es) 2004-12-01
US6348211B1 (en) 2002-02-19
HK1156872A1 (en) 2012-06-22
LV12558B (en) 2001-03-20
JP4316800B2 (ja) 2009-08-19
TW200406231A (en) 2004-05-01
JP2009073856A (ja) 2009-04-09
AU1824999A (en) 1999-07-05
RU2233156C2 (ru) 2004-07-27
TR200001736T2 (tr) 2001-01-22
LV12558A (lv) 2000-11-20
BR9814282A (pt) 2000-10-03
CZ20002209A3 (cs) 2000-11-15
CN1368876A (zh) 2002-09-11
CA2315237A1 (en) 1999-06-24
CZ305817B6 (cs) 2016-03-23
US6210705B1 (en) 2001-04-03
EP2314288B1 (en) 2013-12-11
WO1999030694A3 (en) 1999-08-19
NO20003096D0 (no) 2000-06-15
HUP0004539A3 (en) 2006-06-28
CZ2009132A3 (cs) 2016-03-23
EP2314288A1 (en) 2011-04-27
SI20360B (sl) 2008-06-30
EP1037615B1 (en) 2004-03-03
HU226615B1 (en) 2009-04-28
DE69822199T2 (de) 2005-02-17
WO1999030694A2 (en) 1999-06-24
ATE260652T1 (de) 2004-03-15
TWI242452B (en) 2005-11-01

Similar Documents

Publication Publication Date Title
AR014062A1 (es) COMPOSICION DE METILFENIDATO PARA APLICACIoN TOPICA Y METODO PARA SU PREPARACION
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
BRPI0519748A2 (pt) preparaÇço de curativo para resfriamento tàpico
DE602006016799D1 (de) NEUE, HYALURONSÄURE ODER HYALURONSàURE DERIVATE UND COLLAGENASE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR TOPISCHEN BEHANDLUNG VON WUNDEN, VERBRENNUNGEN UND GESCHWÜREN
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
ATE252367T1 (de) Verfahren und regelung des hautaussehens mit vitamin - b3 - verbindungen
FR2777183B1 (fr) Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
David et al. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream
BRPI0418157A (pt) terapêutica de tumores alogênicos
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
ATE193651T1 (de) Therapeutisches system zur behandlung der psoriasis
ATE480245T1 (de) Verwendung von biokompatiblen polymeren zur herstellung einer zusammenstzung oder eines medizinprodukts
RU2194535C2 (ru) Средство для лечения ран
BRPI0514445A (pt) métodos para cicatrizar feridas administrando il-18 humano
DK0774954T3 (da) Hydrogel til påføring af terapeutisk og/eller kosmetisk aktive stoffer på huden
ES2129999T3 (es) Composicion gelificada estable con elevado contenido en electrolito.
ES2292711T5 (es) Favorecimiento de la reconstrucción celular y/o de la diferenciación celular con azúcar no metabolizable y un absorbente polimérico.
CO4970785A1 (es) Composiciones y metodos para tratar con metilfenidato el deficit de la atencion y el deficit de la atencion con hiperactividad
ES2201941B1 (es) Tratamiento de quemaduras.
BR0008394A (pt) Composição para o tratamento da psorìase
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
FR2884423B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
RU2539420C1 (ru) Способ лечения пародонтита

Legal Events

Date Code Title Description
FC Refusal